ライフサイエンスコーパス: PVI

1 PVI alone was performed in 23 of 85 (27%) patients of gr

2 PVI irrigation for perforated appendicitis in children d

3 PVI offers limited value to OSA patients not treated wit

4 PVI only seems to be sufficient to treat patients with l

5 PVI treatment enhanced wound healing via promotion of ex

6 PVI+CFAE ablation versus PVI alone did not improve the o

7 PVI+GP ablation strategy compared with PVI alone yielded

8 tive on 22 226 patients who underwent 27 048 PVI from August 2007 to May 2013.

9 Overall, 21+/-4 months after 1 PVI session, the sinus rhythm maintenance rate without a

10 Subjects were randomized as follows: arm 1, PVI + ablation of non-PV triggers identified using a sti

11 olymer [Os(4,4'-dimethyl-2,2'-bipyridine)(2)(PVI)Cl](+) had a potential of +309 mV versus NHE, and th

12 Atrial tachyarrhythmias recurred in 28 PVI-only group patients and 24 Substrate-modification gr

13 It has been found that 0.5% PVI can attenuate congestion, edema and pain induced by

14 e data show that topical application of 0.5% PVI could promote acute skin wound healing though increa

15 other two were dressed with gauze with 0.5% PVI for 1 hour per day for the first 5 days after injury

16 431542 and all wounds were treated with 0.5% PVI for 5 days.

17 is study aimed to assess the effects of 0.5% PVI on acute skin wounds.

18 Continuous electric activity ablation+PVI result in a similar incidence of acute AF terminatio

19 cantly lower using generalized CFAE ablation+PVI.

20 predicted arrhythmia recurrences, and acute PVI responders had a reduced risk of relapse (hazard rat

21 itional ablation was performed only in acute PVI nonresponder, if direct current cardioversion failed

22 In 25 patients, acute PVI (96 of 96 pulmonary veins [PVs]; mean ablation time:

23 Acutely, PVI was achieved in 36 of 40 PVs (90%).

24 as (AT) in patients with persistent AF after PVI.

25 eral factors independently predict ASC after PVI.

26 lore the risk of cardiovascular events after PVI in patients with and without guideline-recommended a

27 if direct current cardioversion failed after PVI.

28 y at baseline, in the left atrium (LA) after PVI and linear lesions (roof and mitral isthmus), and bi

29 fibrillation substrate, linear lesions after PVI diminished the target area for CFE ablation, and com

30 rate of electric reconduction 3 months after PVI is high in patients with initially isolated PVs.

31 nce of >/=142 PACs per day at 6 months after PVI was independently associated with a significantly in

32 epeat electrophysiology study 2 months after PVI, regardless of symptoms, to document the number of r

33 o COM with respect to clinical outcome after PVI and resulted in reduced fluoroscopy time and radiati

34 ignificantly improved patient outcomes after PVI.

35 ost likely to experience AF recurrence after PVI.

36 ions, defined as CFE area, was reduced after PVI (18.3+/-12.03 to 10.2+/-7.1 cm(2); P<0.001) and agai

37 Elimination of extra-PV AF sources after PVI is superior to sole PV isolation with the adjunct of

38 re, identify factors predicting stroke after PVI, and explore the risk of cardiovascular events after

39 iscontinuing anticoagulation treatment after PVI in association with the CHA2DS2-VASc (congestive hea

40 discontinuation of warfarin treatment after PVI is not safe in high-risk patients, especially those

41 lationship between ERAT beyond 4 weeks after PVI and postblanking AT recurrence merits further invest

42 ERAT occurring beyond 4 weeks after PVI is associated with PVrc and particularly of PVrc of

43 zed that ERAT occurring beyond 4 weeks after PVI is associated with PVrc at repeat electrophysiology

44 ta-blockers, were discontinued 4 weeks after PVI.

45 were followed up for more than 1 year after PVI.

46 interval 0.24, 1.02)] and also to alcoholic PVI, although uncertainty was larger [RR 0.51 (95% confi

47 ive strategies comprising either stand-alone PVI (PVI-only approach) or a stepwise approach of PVI fo

48 en an index ablative approach of stand-alone PVI and a stepwise approach of PVI plus complex fraction

49 Patients were randomized 1:1 to stand-alone PVI or PVI plus substrate modification.

50 fibrosis ablation (CMR group) or PVI alone (PVI-alone group).

51 The relative efficacy of CHG and PVI based skin antiseptics in clean surgery remains uncl

52 effect of different preparations of CHG and PVI on the dichotomous outcome of surgical site infectio

53 edural outcomes (procedure, fluoroscopy, and PVI times) were comparable between the 3 arms.

54 +/- 5 min, and 23 +/- 5 min for PVI, GP, and PVI+GP groups, respectively (p < 0.001).

55 ), and 61 (74%) patients in the PVI, GP, and PVI+GP groups, respectively (p = 0.004 by log-rank test)

56 ssed the safety and effectiveness of LEB and PVI in patients with symptomatic claudication and critic

57 nts with discrepancies between CAC score and PVI rank quartiles had a higher percentage of soft and f

58 atabases for studies on ostial versus antral PVI.

59 ostial isolation of the PVs and wide antral PVI.

60 ical site infection when compared to aqueous PVI [RR 0.49 (95% confidence interval 0.24, 1.02)] and a

61 HG seem to be safe and twice as effective as PVI (alcoholic or aqueous solutions) in preventing infec

62 In group B, PVI was performed with the patient either in spontaneous

63 nt second-generation 28-mm cryoballoon-based PVI in 2 centers (St. George's hospital and Harburg hosp

64 ul second-generation 28-mm cryoballoon-based PVI were included in this analysis.

65 ted] Dabigatran was held 1 to 2 doses before PVI and restarted at the conclusion of the procedure or

66 ed computational modeling to predict, before PVI, which patients are most likely to experience AF rec

67 hat additional substrate modification beyond PVI does not improve single-procedure efficacy in patien

68 rtium Peripheral Vascular Intervention (BMC2 PVI) database, we identified 1357 peripheral vascular in

69 lity of pulsed field ablation (PFA) for both PVI and LAPW ablation in persistent AF.

70 and impaired mitochondrial function in both PVI and pyramidal cells.

71 s electric activity were ablated followed by PVI.

72 Circumferential PVI using irrigated radiofrequency current was performed

73 nd randomized as follows: 1) circumferential PVI (n = 78); 2) anatomic ablation of the main left atri

74 ft atrial GP (n = 82); or 3) circumferential PVI followed by anatomic ablation of the main left atria

75 trogram-based ablation after circumferential PVI isolation.

76 This retrospective cohort study compared PVI procedures using a novel high-density mapping system

77 m effects meta-analysis of studies comparing PVI versus PVI+CFAE ablation.

78 ablation line, whereas in group B, complete PVI without any gaps was intended.

79 .001), for a difference in favor of complete PVI of 17.1% (95% confidence interval, 5.3%-28.9%).

80 his study proves the superiority of complete PVI over incomplete PVI with respect to AF recurrence wi

81 d to either incomplete (group A) or complete PVI (group B).

82 Shield of Michigan Cardiovascular Consortium PVI registry.

83 Conventional PVI transects the major left atrial GP, and it is possib

84 n to PVI is more effective than conventional PVI-only strategy for persistent AF.

85 schizophrenia and autism spectrum disorder, PVI circuits are altered in these psychiatric disorders.

86 When "wired" with Os(dmbpy)PVI, the graphite electrodes modified with fdgPDH showed

87 ne)2(poly(vinylimidazole))10Cl](+) [Os(dmbpy)PVI] and [Os(4,4'-dimethoxy-2,2'-bipyridine)2(poly-(viny

88 )2(poly-(vinylimidazole))10Cl](+) [Os(dmobpy)PVI].

89 enetic manipulation reveals that brief dmPFC-PVI activation triggers an active social approach to pro

90 Juvenile social isolation decouples dmPFC-PVI activation from subsequent active social approach by

91 Chemogenetic activation of dmPFC-PVI activity in the adult animal mitigates juvenile isol

92 ial experience-dependent maturation of dmPFC-PVI is linked to long-term impacts on social behavior.

93 PFA potentiated efficient, safe, and durable PVI and LAPW ablation.

94 C within 60 s independently predict durable PVI.

95 Termination of AF during PVI was observed in 31 (65%) patients, whereas AF persis

96 ents were prospectively randomized to either PVI alone (n = 78) or full defrag (n = 75), with 52 pati

97 tly higher success rate compared with either PVI or GP alone in patients with PAF.

98 lysis of patients undergoing lower extremity PVI in the Vascular Quality Initiative (2017-2018) was p

99 on or on DAPT at the time of lower extremity PVI, prescription of DAPT following intervention is ~50%

100 DAPT prescription following lower extremity PVI.

101 rrhythmic drugs or repeat ablation following PVI (65.6% vs. 33.3%; p = 0.02).

102 AF recurrence following PVI in CPAP nonuser patients was significantly higher (H

103 likely to experience AF recurrence following PVI, even when the patient cohort is small.

104 SA is a predictor of AF recurrence following PVI.

105 CFE area was progressively reduced following PVI and linear lesions, and LA ablation reduced right at

106 Interleukin 6 was reduced following PVI treatment.

107 For PVI, all 4 PV antra were isolated with confirmed entranc

108 bipolar PFA using a multispline catheter for PVI and LAPW ablation under intracardiac echocardiograph

109 et lesion revascularization were greater for PVI than for LEB in patients presenting with claudicatio

110 /- 3 min, 20 +/- 5 min, and 23 +/- 5 min for PVI, GP, and PVI+GP groups, respectively (p < 0.001).

111 pping catheter were used in all patients for PVI.

112 ne and 100 consecutive patients referred for PVI.

113 al study, whatever the power output used for PVI.

114 Currently, 2 main approaches are used for PVI: ostial isolation of the PVs and wide antral PVI.

115 ophilin D (CypD) show robust protection from PVI dysfunction following perinatal NMDAR blockade.

116 These results suggest that HDM-guided PVI is effective and safe for AF ablation.

117 specific molecular divergence of hippocampal PVI subtypes, suggesting that activation of GABA(B)Rs ma

118 groups: 5.1% in PVI, 4.9% in GP, and 6.1% in PVI+GP.

119 utter did not differ between groups: 5.1% in PVI, 4.9% in GP, and 6.1% in PVI+GP.

120 in for the periprocedural anticoagulation in PVI.

121 creases in ROS and the resulting deficits in PVI function, and changes in excitatory and inhibitory s

122 benefit in reduction of total 30-day LOS in PVI patients was 96% and was significant (P = 0.05) on f

123 superiority of complete PVI over incomplete PVI with respect to AF recurrence within 3 months.

124 in isolation (PVI) is superior to incomplete PVI with regard to the patients' clinical outcome.

125 During the index PVI, the standard freeze cycle duration was 240 s.

126 The coronary plaque volume index (PVI) was determined by dividing the wall volume by the c

127 or fetal periventricular venous infarction (PVI) were recruited.

128 "hub" affecting parvalbumine interneurones (PVI) and their perineuronal nets (PNN) (Lancet Psychiatr

129 n of parvalbumin (PV)-positive interneurons (PVI), and long-lasting physiological and behavioral chan

130 rgic parvalbumin (PV)-positive interneurons (PVI), which are crucial for the coordination of neuronal

131 Peripheral vascular intervention (PVI) is an effective treatment option for patients with

132 related to peripheral vascular intervention (PVI) procedures.

133 following peripheral vascular intervention (PVI), there are limited data on antiplatelet prescribing

134 cations of peripheral vascular intervention (PVI); however, their incidence and risk factors remain u

135 to test the hypothesis that povidone-iodine (PVI) irrigation versus no irrigation (NI) reduces postop

136 Povidone-iodine (PVI) is principally used as an antimicrobial agent.

137 ic nerve, and esophagus during PV isolation (PVI) using the second-generation cryoballoon are not kno

138 y achievement while performing PV isolation (PVI).

139 ther randomized to pulmonary vein isolation (PVI) (n = 62) or the biatrial maze procedure (n = 64).

140 fibrillation (AF), pulmonary vein isolation (PVI) alone is considered insufficient for many patients

141 e survival between pulmonary vein isolation (PVI) and a stepwise approach (full defrag) consisting of

142 in achieving acute pulmonary vein isolation (PVI) and favorable clinical outcome.

143 eve more effective pulmonary vein isolation (PVI) and minimize arrhythmia recurrence after atrial fib

144 nking period after pulmonary vein isolation (PVI) as early recurrence of atrial tachyarrhythmia (ERAT

145 Pulmonary vein isolation (PVI) as interventional treatment for atrial fibrillation

146 delivers effective pulmonary vein isolation (PVI) associated with superior 1-year clinical outcome.

147 involving not only pulmonary vein isolation (PVI) but also additional linear lesions and ablation of

148 on of conventional pulmonary vein isolation (PVI) by circumferential antral ablation with ganglionate

149 Pulmonary vein isolation (PVI) for atrial fibrillation is associated with a transi

150 Pulmonary vein isolation (PVI) for persistent atrial fibrillation is associated wi

151 t decade, electric pulmonary vein isolation (PVI) has become a procedure implemented worldwide for th

152 ion in addition to pulmonary vein isolation (PVI) in patients undergoing ablation for AF.

153 Pulmonary vein isolation (PVI) is a recommended treatment for patients with atrial

154 Pulmonary vein isolation (PVI) is an effective treatment strategy for patients wit

155 cedure efficacy of pulmonary vein isolation (PVI) is less than optimal in patients with persistent at

156 Pulmonary vein isolation (PVI) is still associated with a substantial number of ar

157 n whether complete pulmonary vein isolation (PVI) is superior to incomplete PVI with regard to the pa

158 durability of the pulmonary vein isolation (PVI) lines, but also the pathophysiological understandin

159 hypothesized that pulmonary vein isolation (PVI) plus ablation of selective atrial low-voltage sites

160 pite the fact that pulmonary vein isolation (PVI) should be performed prophylactically for all pulmon

161 osed to facilitate pulmonary vein isolation (PVI), high-power ablation may favor extracardiac damage.

162 rial fibrosis plus pulmonary vein isolation (PVI).

163 blated followed by pulmonary vein isolation (PVI).

164 a (OSA) undergoing pulmonary vein isolation (PVI).

165 ce is common after pulmonary vein isolation (PVI).

166 as circumferential pulmonary vein isolation (PVI).

167 were referred for pulmonary vein isolation (PVI).

168 urther applications to ensure a long-lasting PVI.

169 % female) who underwent lower extremity (LE)-PVI from 2004 to 2009 at 16 hospitals participating in t

170 ificant proportion of patients undergoing LE-PVI, have a more severe and complex disease process, and

171 eral artery disease, in comparison with LEB, PVI was associated with fewer 30-day procedural complica

172 procedural success compared with men, making PVI an effective treatment strategy among women with LE-

173 curred in 1 (1%) patient 2 days after manual PVI.

174 In 1 patient undergoing manual PVI (1%), an SCL with asymptomatic subarachnoid hemorrha

175 similar after RA-PVI as compared with manual PVI.

176 n isolation (RA-PVI) as compared with manual PVI.

177 derwent high-density atrial voltage mapping, PVI, and ablation at low-voltage areas (LVA < 0.5 mV in

178 The mean PVI (+/-standard deviation) was 11.2 mm(2) +/- 2.7.

179 vity may play an integral role in modulating PVI-mediated cognitive processes.SIGNIFICANCE STATEMENT

180 ents randomized to MVS alone, 16.1% in MVS + PVI, and 25% in MVS + biatrial maze.

181 PVI-only approach) or a stepwise approach of PVI followed by complex fractionated atrial electrogram

182 f stand-alone PVI and a stepwise approach of PVI plus complex fractionated atrial electrogram and lin

183 The procedure in group A consisted of PVI exclusively.

184 tepwise approach (full defrag) consisting of PVI, ablation of complex fractionated electrograms, and

185 n schizophrenia, we show that dysfunction of PVI signaling in the PFC specifically produces deficits

186 hibition of TGF beta abolished the effect of PVI treatment on wound closure.

187 tion plays a central role in the efficacy of PVI.

188 rations and rescued the normal maturation of PVI/PNN, even if performed after an additional insult th

189 The rate of PVI declined in inpatient settings from 209.7 to 151.6 (

190 The annual rate of PVI increased slightly from 401.4 to 419.6 per 100,000 M

191 , we examined age- and sex-adjusted rates of PVI by year, type of procedure, clinical setting, and ph

192 From 2006 to 2011, overall rates of PVI increased minimally.

193 e trends in the use and clinical settings of PVI and the effect of changes in reimbursement.

194 procedures were similar across all types of PVI, whereas mean costs of atherectomy procedures in out

195 o encourage more efficient outpatient use of PVI in the United States.

196 were performed for </=2 deliveries based on PVI without a bonus freeze.

197 e stress and neuroinflammation, impacting on PVI/PNN integrity.

198 ABA(B)Rs was also present at lower levels on PVI axon terminals.

199 However, the impact of CPAP therapy on PVI outcome in patients with OSA is poorly known.

200 CMR-guided fibrosis ablation (CMR group) or PVI alone (PVI-alone group).

201 ting patients were randomized to PVI only or PVI with renal artery denervation.

202 ts were randomized 1:1 to stand-alone PVI or PVI plus substrate modification.

203 ized due to AF termination with the original PVI.

204 ntral approach is more effective than ostial PVI in achieving freedom from total atrial tachyarrhythm

205 not seem to provide additional benefit over PVI alone in patients with persistent AF, but it is asso

206 the study group displayed higher first-pass PVI (92% versus 73%; P<0.001), lower acute pulmonary vei

207 In 105 patients, PVI was the sole ablative therapy, 49 (46.7%) of those p

208 Percutaneous PVI is frequently performed for the treatment of periphe

209 Persistent PVI could be documented in 90 of 115 PVs (78.2%).

210 eevaluation to assess the rate of persistent PVI.

211 is associated with a high rate of persistent PVI.

212 targeting CMR-detected atrial fibrosis plus PVI was not more effective than PVI alone in an unselect

213 ) which is modified with polyvinylimidazole (PVI).

214 or analysis, with 49% initiated on DAPT post-PVI.

215 ts at increased risk of ASC may improve post-PVI outcomes.

216 ociated with an increased likelihood of post-PVI DAPT prescription.

217 clinical implications for the design of post-PVI follow-up.

218 redict the probability of AF recurrence post-PVI.

219 Conclusions High-power PVI guided by unipolar signal modification safely decrea

220 Features were derived from pre-PVI late gadolinium enhanced magnetic resonance images a

221 gether to accurately predict, using only pre-PVI late gadolinium enhanced magnetic resonance imaging

222 >75 years, female sex, white race, no prior PVI, nonfemoral arterial access site, >6-Fr sheath size,

223 atrial fibrillation ablation by prophylactic PVI along with SVCI was almost the same as with the conv

224 trategies comprising either stand-alone PVI (PVI-only approach) or a stepwise approach of PVI followe

225 d size of SCL appears to be similar after RA-PVI as compared with manual PVI.

226 ically assisted pulmonary vein isolation (RA-PVI) as compared with manual PVI.

227 f SCLs was similar in patients undergoing RA-PVI as compared with manually ablated patients (n=9, 18%

228 Fifty patients underwent RA-PVI and 20 patients underwent a manual approach.

229 on were randomized in a 1:1 basis to receive PVI plus CMR-guided fibrosis ablation (CMR group) or PVI

230 However, after changes in reimbursement, PVI and atherectomy in outpatient facilities and office-

231 e undergoing PVI only and patients requiring PVI+selective low-voltage ablation (P = 0.42).

232 ompared to a group of patients from the same PVI cohort without OSA.

233 antly lower in wide antral than in segmental PVI group (odds ratio, 0.42; 95% confidence interval, 0.

234 etiological aspects of these disorders show PVI deficits to be all accompanied by oxidative stress i

235 After successful PVI, a bonus freeze cycle of 240 s was applied in the fi

236 his information may be useful for successful PVI without severe complications.

237 tional insult that exacerbated the long term PVI/PNN impairments.

238 ibrosis plus PVI was not more effective than PVI alone in an unselected population undergoing atrial

239 procedure, yields higher success rates than PVI or GP ablation alone, in patients with paroxysmal at

240 ow-voltage sites may be more successful than PVI only.

241 Our primary finding is that PVI performed with a wide antral approach is more effect

242 sian analysis estimates 89% probability that PVI reduces IAA.

243 The PVI arm had 12% postoperative IAA versus 16% in the NI a

244 The PVI was related to age (standardized beta = 0.32, P < .0

245 The use of pacing to ensure UE along the PVI line markedly improved near-term single-procedure su

246 The relationship between the PVI and cardiovascular risk factors was determined with

247 t was seen in all secondary outcomes for the PVI arm: fewer ED visits and readmissions, and shorter i

248 enervation without significant change in the PVI only group.

249 56%), 39 (48%), and 61 (74%) patients in the PVI, GP, and PVI+GP groups, respectively (p = 0.004 by l

250 ts received the assigned intervention in the PVI-alone and CMR group, respectively.

251 performed in 80% and 71% of patients in the PVI-alone and CMR groups, respectively.

252 e was achieved in 21 patients (27.6%) in the PVI-alone group and 22 patients (27.8%) in the CMR group

253 ablations were performed (mean: 1.59 in the PVI-alone group, 1.55 in the full-defrag group).

254 erse events (3 in the CMR group and 2 in the PVI-alone group; P=0.68).

255 4% (95% confidence interval, 43%-68%) in the PVI-only and 57% (95% confidence interval, 46%-72%) in t

256 Twenty-four patients in the PVI-only group (39%) and 18 in the Substrate-modificatio

257 ion versus 4 (29%) of the 14 patients in the PVI-only group (p = 0.033).

258 patients included in the analysis (61 in the PVI-only group, 57 in the Substrate-modification group).

259 rite-ion was investigated by using CV on the PVI modified CPE.

260 l atrial fibrillation) were allocated to the PVI-alone group (N=76) or CMR group (N=79).

261 orated appendicitis were randomized (1:1) to PVI or NI from April 2016 to March 2017 and followed for

262 Addition of GP ablation to PVI confers a significantly higher success rate compared

263 within/at borderzones of LVA in addition to PVI is more effective than conventional PVI-only strateg

264 The role of CFAE ablation in addition to PVI should be questioned and other alternatives assessed

265 Selective atrial ablation in addition to PVI was performed in 62 patients with termination of AF

266 in all cases prophylactically in addition to PVI.

267 chondrial redox regulation can contribute to PVI dysfunction.

268 were only observed with patients exposed to PVI.

269 s a common pathological mechanism leading to PVI impairment in schizophrenia and some forms of autism

270 Consenting patients were randomized to PVI only or PVI with renal artery denervation.

271 nts were enrolled, and 14 were randomized to PVI only, and 13 were randomized to PVI with renal arter

272 mized to PVI only, and 13 were randomized to PVI with renal artery denervation.

273 own about sex-related differences related to PVI procedures.

274 CFE (mean cycle length </=120 ms) remote to PVI and linear lesions, defined as CFE area, was reduced

275 At receiver-operator curve analysis, time to PVI <60 s identified the absence of PV reconduction (sen

276 In the multivariable analysis, time to PVI (P=0.03) and failure to achieve -40 degrees C within

277 In addition, 60-s cut-off for time to PVI indicates persistent isolation with 96.4% negative p

278 h paroxysmal atrial fibrillation who undergo PVI and leads to a substantial midterm sinus rhythm main

279 patients with atrial fibrillation undergoing PVI from the Swedish Catheter Ablation Register were inc

280 systems, we compared 883 patients undergoing PVI and 975 patients undergoing LEB between January 1, 2

281 dural anticoagulation in patients undergoing PVI compared with uninterrupted warfarin therapy.

282 important therapy in OSA patients undergoing PVI that improves arrhythmia free survival.

283 total of 999 consecutive patients undergoing PVI were included; 376 patients were on dabigatran (150

284 ith a control group (66 patients) undergoing PVI only (group II).

285 with a low amount of low voltage undergoing PVI only and patients requiring PVI+selective low-voltag

286 Identifying mechanism(s) underlying PVI deficits is essential to establish treatments target

287 Twenty dogs underwent PVI using second-generation cryoballoon.

288 ith paroxysmal atrial fibrillation underwent PVI using Carto and Lasso.

289 years old, 40 men), who previously underwent PVI following the standard approach of our institution,

290 with documented paroxysmal AF who underwent PVI and had preprocedural late gadolinium enhanced magne

291 Among 426 patients who underwent PVI between 2007 and 2010, 62 patients had a polysomnogr

292 PVI+CFAE ablation versus PVI alone did not improve the overall rate of freedom fr

293 eta-analysis of studies comparing PVI versus PVI+CFAE ablation.

294 tudied: 46 with NAIS, 34 with APPIS, 55 with PVI, and 77 controls (male, 53%; median age, 4.8 years).

295 nd reduces AF recurrences when combined with PVI.

296 PVI+GP ablation strategy compared with PVI alone yielded a hazard ratio of 0.53 (95% confidence

297 However, in comparison with PVI, LEB was associated with increased rates of complica

298 If AF did not terminate with PVI, ablation was continued by targeting extra-PV AF sou

299 Nine of the 13 patients (69%) treated with PVI with renal denervation were AF-free at the 12-month

300 .001) were observed in patients treated with PVI with renal denervation without significant change in